Patents by Inventor Steven Do

Steven Do has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Testing of analog neural memory cells in an artificial neural network
    Patent number: 12205655
    Abstract: In one example, a method of testing a plurality of non-volatile memory cells in an array of non-volatile memory cells, wherein the array is arranged in rows and columns, wherein each row is coupled to a word line and each column is coupled to a bit line, and wherein each word line is selectively coupled to a row decoder and each bit line is selectively coupled to a column decoder, comprises asserting, by the row decoder, all word lines in the array; asserting, by the column decoder, all bit lines in the array; performing a deep programming operation on the array of non-volatile memory cells; and measuring a total current received from the bit lines.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: January 21, 2025
    Assignee: SILICON STORAGE TECHNOLOGY, INC.
    Inventors: Hieu Van Tran, Thuan Vu, Stephen Trinh, Stanley Hong, Anh Ly, Steven Lemke, Nha Nguyen, Vipin Tiwari, Nhan Do
  • OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER
    Publication number: 20240383915
    Abstract: Provided herein are acyclic oxazepinyl compounds useful in the treatment on cancers.
    Type: Application
    Filed: April 6, 2022
    Publication date: November 21, 2024
    Applicant: Genentech, Inc.
    Inventors: Lewis J. GAZZARD, Samantha Alyson GREEN, Elizabeth H. KELLEY, Matthew Leo LANDRY, Sushant MALHOTRA, Benjamin David RAVETZ, Michael SIU, Jack Alexander TERRETT, BinQing WEI, Steven DO, Yun-Xing CHENG, Limin CHENG, Jianfeng XIN, Mingtao HE, Guosheng WU, Yinlei SUN, Cheng SHAO, Aijun LU, Yulai ZHANG
  • AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF
    Publication number: 20240368186
    Abstract: Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.
    Type: Application
    Filed: May 28, 2024
    Publication date: November 7, 2024
    Inventors: Matthew Leo Landry, Christian Nilewski, Michael Siu, Elisia Villemure, Yong Wang, BinQing Wei, Melissa Ann Ashley, Steven Do, Lewis John Gazzard, Samantha Alyson Green
  • Fused ring compounds
    Patent number: 12084429
    Abstract: This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: September 10, 2024
    Assignee: Genentech, Inc.
    Inventors: Sushant Malhotra, Jianfeng Xin, Steven Do, Jack Terrett
  • AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF
    Publication number: 20240025919
    Abstract: Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.
    Type: Application
    Filed: May 19, 2023
    Publication date: January 25, 2024
    Inventors: Matthew Leo Landry, Christian Nilewski, Michael Siu, Elisia Villemure, Yong Wang, BinQing Wei, Melissa Ann Ashley, Steven Do, Lewis John Gazzard, Samantha Alyson Green
  • Fused ring compounds
    Patent number: 11760744
    Abstract: Provided are fused ring compounds of Formula (I), Formula (II), or Formula (III), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods treatment by their administration.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: September 19, 2023
    Assignee: Genentech, Inc.
    Inventors: Aijun Lu, Sushant Malhotra, Alan G. Olivero, Cheng Shao, Yamin Zhang, Steven Do
  • FUSED RING COMPOUNDS
    Publication number: 20230089126
    Abstract: This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
    Type: Application
    Filed: December 17, 2021
    Publication date: March 23, 2023
    Inventors: Sushant Malhotra, Jianfeng Xin, Steven Do, Jack Terrett
  • FUSED RING COMPOUNDS
    Publication number: 20230002345
    Abstract: Provided are fused ring compounds of Formula (I), Formula (II), or Formula (III), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods treatment by their administration.
    Type: Application
    Filed: August 15, 2019
    Publication date: January 5, 2023
    Inventors: Aijun LU, Sushant Malhotra, Alan G. Olivero, Cheng Shao, Yamin Zhang, Steven Do
  • TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF
    Publication number: 20220281893
    Abstract: Provided herein are tetracyclic oxazepinyl compounds useful in the treatment on cancers.
    Type: Application
    Filed: February 7, 2022
    Publication date: September 8, 2022
    Applicant: Genentech, Inc.
    Inventors: Lewis J. GAZZARD, Samantha Alyson GREEN, Matthew Leo LANDRY, Sushant MALHOTRA, Michael SIU, Steven DO, Yun-Xing CHENG, Limin CHENG, Jianfeng XIN, Mingtao HE
  • HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20220226326
    Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: August 23, 2021
    Publication date: July 21, 2022
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Leivers, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do
  • Serine/threonine kinase inhibitors
    Patent number: 11376260
    Abstract: Compounds having the formula I wherein R1, X1, X2, X3 and X4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: July 5, 2022
    Assignee: Genentech, Inc.
    Inventors: Aleksandr Kolesnikov, Steven Do
  • Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators
    Patent number: 11236046
    Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: February 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Yanyan Chu, Steven Do, Anthony Estrada, Baihua Hu, Aleksandr Kolesnikov, Xingyu Lin, Joseph P. Lyssikatos, Daniel Shore, Vishal Verma, Lan Wang, Guosheng Wu, Po-wai Yuen
  • Fused ring compounds
    Patent number: 11236068
    Abstract: This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: February 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Sushant Malhotra, Jianfeng Xin, Steven Do, Jack Terrett
  • FUSED RING COMPOUNDS
    Publication number: 20210230142
    Abstract: This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
    Type: Application
    Filed: November 8, 2019
    Publication date: July 29, 2021
    Inventors: Sushant Malhotra, Jianfeng Xin, Steven Do, Jack Terrett
  • Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators
    Patent number: 11034698
    Abstract: Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: June 15, 2021
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Steven Do, Joy Drobnick, Alberto Gobbi, Tamiko Katsumoto, James Richard Kiefer, Jr., Jun Liang, Naomi S. Rajapaksa, Yongsheng Chen, Liqiang Fu, Kwong Wah Lai, Zhiguo Liu, John Wai, Fei Wang
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20210106593
    Abstract: Compounds having the formula I wherein R1, X1, X2, X3 and X4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Application
    Filed: October 20, 2020
    Publication date: April 15, 2021
    Applicant: GENENTECH, INC.
    Inventors: Aleksandr Kolesnikov, Steven Do
  • IRAK4 modulators
    Patent number: 10899772
    Abstract: Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: January 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Steven Do, Tamiko Katsumoto, Jun Liang, Naomi S. Rajapaksa, James Richard Kiefer, Jr., Liqiang Fu
  • Serine/threonine kinase inhibitors
    Patent number: 10842799
    Abstract: Compounds having the formula I wherein R1, X1, X2, X3 and X4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: November 24, 2020
    Assignee: GENENTECH, INC.
    Inventors: Aleksandr Kolesnikov, Steven Do
  • HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20200345735
    Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: January 7, 2020
    Publication date: November 5, 2020
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Leivers, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do
  • PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
    Publication number: 20200123166
    Abstract: Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 23, 2020
    Applicant: Genentech, Inc.
    Inventors: Marian C. BRYAN, Steven DO, Joy DROBNICK, Alberto GOBBI, Tamiko KATSUMOTO, James Richard KIEFER, Jr., Jun LIANG, Naomi S. RAJAPAKSA, Yongsheng CHEN, Liqiang FU, Kwong Wah LAI, Zhiguo LIU, John WAI, Fei WANG